Bioton SA shareholders approved the proposed acquisition of SciGen Ltd. by YiFan International Pharmaceutical Co. Ltd.
Poland's Bioton is the holding company of SciGen, a Singapore-based developer of genetically engineered biopharmaceutical products.
YiFan previously made a preconditional offer for all of SciGen's ordinary shares at 5.07 U.S. cents per share.
